
Grail Investors Face Securities Lawsuit After NHS-Galleri Trial Failure
A securities class action lawsuit against Grail, Inc. alleges the company misled investors regarding the efficacy of its NHS-Galleri trial. Following the disclosure that the study failed to meet its primary endpoint of reducing late-stage cancers, shares plummeted 50.55% in a single day, wiping out $51.32 per share.
























